Literature DB >> 22298303

Progress in global measles control, 2000-2010.

.   

Abstract

In 1980, before widespread global use of measles vaccine, an estimated 2.6 million measles deaths occurred worldwide. In 2001, to accelerate the reduction in measles cases achieved by vaccination, the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) developed a strategy to deliver 2 doses of measles-containing vaccine (MCV) to all children through routine services and supplementary immunization activities (SIAs) and improved disease surveillance. After implementation of this strategy, the estimated number of annual measles deaths worldwide decreased from 733,000 in 2000 to 164,000 in 2008. In 2010, the World Health Assembly endorsed the following measles objectives for 2015: 1) raise routine coverage with the first dose of MCV (MCV1) for children aged 1 year to ≥90% nationally and ≥80% in every district or equivalent administrative unit, 2) reduce and maintain annual measles incidence at <5 cases per million, and 3) reduce measles mortality by ≥95% from the 2000 estimate. During 2000-2010, global MCV1 coverage increased from 72% to 85% with approximately 1 billion children vaccinated during measles SIAs. Reported measles cases decreased from 2000 to 2008, remained stable in 2009, and increased in 2010. By the end of 2010, 40% of countries still had not met the incidence target of <5 cases per million. Key challenges must be overcome to meet the 2015 objectives, including 1) declining political and financial commitments to measles control, 2) failure to reach uniform high coverage with 2 doses of MCV through routine services or SIAs, and 3) inadequate monitoring subnationally of coverage with the first and second dose of MCV to guide interventions to increase coverage.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22298303

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  12 in total

1.  Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins.

Authors:  Fernando P Polack; Shari L Lydy; Sok-Hyong Lee; Paul A Rota; William J Bellini; Robert J Adams; Harriet L Robinson; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

2.  Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells.

Authors:  Ianko D Iankov; Alan R Penheiter; Guy E Griesmann; Stephanie K Carlson; Mark J Federspiel; Evanthia Galanis
Journal:  Virus Res       Date:  2012-12-21       Impact factor: 3.303

3.  Epidemiology of two large measles virus outbreaks in Catalonia: what a difference the month of administration of the first dose of vaccine makes.

Authors:  Núria Torner; Andres Anton; Irene Barrabeig; Sara Lafuente; Ignasi Parron; César Arias; Neus Camps; Josep Costa; Ana Martínez; Roser Torra; Pere Godoy; Sofia Minguell; Glòria Ferrús; Carmen Cabezas; Ángela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2013-01-09       Impact factor: 3.452

4.  Strengthening the expanded programme on immunization in Africa: looking beyond 2015.

Authors:  Shingai Machingaidze; Charles S Wiysonge; Gregory D Hussey
Journal:  PLoS Med       Date:  2013-03-19       Impact factor: 11.069

5.  Measles: A Canary in the Coal Mines?

Authors:  Jacob John
Journal:  Indian J Pediatr       Date:  2016-01-26       Impact factor: 5.319

6.  Molecular characterisation of measles virus strains among refugees from Central African Republic in Cameroon in 2014.

Authors:  P K Ndombo; V N Ndze; F D Mbarga; R Anderson; A Acho; J Ebua Chia; A K Njamnshi; P A Rota; D Waku-Kouomou
Journal:  Epidemiol Infect       Date:  2018-01-09       Impact factor: 4.434

7.  Measles outbreak in Northern Central African Republic 3 years after the last national immunization campaign.

Authors:  Vianney Tricou; Marilou Pagonendji; Casimir Manengu; Jeff Mutombo; Rock Ouambita Mabo; Ionela Gouandjika-Vasilache
Journal:  BMC Infect Dis       Date:  2013-02-26       Impact factor: 3.090

8.  Molecular evolution of hemagglutinin (H) gene in measles virus genotypes D3, D5, D9, and H1.

Authors:  Mika Saitoh; Makoto Takeda; Koichi Gotoh; Fumihiko Takeuchi; Tsuyoshi Sekizuka; Makoto Kuroda; Katsumi Mizuta; Akihide Ryo; Ryota Tanaka; Haruyuki Ishii; Hayato Takada; Kunihisa Kozawa; Ayako Yoshida; Masahiro Noda; Nobuhiko Okabe; Hirokazu Kimura
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

9.  Immunization coverage and predictive factors for complete and age-appropriate vaccination among preschoolers in Athens, Greece: a cross--sectional study.

Authors:  Ioanna D Pavlopoulou; Koralia A Michail; Evangelia Samoli; George Tsiftis; Konstantinos Tsoumakas
Journal:  BMC Public Health       Date:  2013-10-02       Impact factor: 3.295

10.  Epidemiology of laboratory confirmed measles virus cases in Amhara Regional State of Ethiopia, 2004-2014.

Authors:  Mekonen Getahun; Berhane Beyene; Ayesheshem Ademe; Birke Teshome; Mesfin Tefera; Anjelo Asha; Aklog Afework; Yoseph HaileMariyam; Esete Assefa; Kathleen Gallagher
Journal:  BMC Infect Dis       Date:  2016-03-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.